An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

Avian influenza: A vaccine for a deadly emergent strain A vaccine candidate to treat a deadly subtype of avian influenza was shown to induce protective antibodies in initial clinical trials. As of March 2017, avian influenza strain A/H7N9 has killed 497 people since 2013, with 1349 confirmed cases....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Adam D. DeZure, Emily E. Coates, Zonghui Hu, Galina V. Yamshchikov, Kathryn L. Zephir, Mary E. Enama, Sarah H. Plummer, Ingelise J. Gordon, Florence Kaltovich, Sarah Andrews, Adrian McDermott, Michelle C. Crank, Richard A Koup, Richard M. Schwartz, Robert T. Bailer, Xiangjie Sun, John R. Mascola, Terrence M. Tumpey, Barney S. Graham, Julie E. Ledgerwood
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e2d2da024d7c4739ac5a7e10fb271246
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e2d2da024d7c4739ac5a7e10fb271246
record_format	dspace
spelling	oai:doaj.org-article:e2d2da024d7c4739ac5a7e10fb2712462021-12-02T16:20:00ZAn avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial10.1038/s41541-017-0016-62059-0105https://doaj.org/article/e2d2da024d7c4739ac5a7e10fb2712462017-06-01T00:00:00Zhttps://doi.org/10.1038/s41541-017-0016-6https://doaj.org/toc/2059-0105Avian influenza: A vaccine for a deadly emergent strain A vaccine candidate to treat a deadly subtype of avian influenza was shown to induce protective antibodies in initial clinical trials. As of March 2017, avian influenza strain A/H7N9 has killed 497 people since 2013, with 1349 confirmed cases. Julie Ledgerwood and her team from the United States’ National Institutes of Health in collaboration with colleagues at the Centers for Disease Control and Prevention tested their two-stage vaccine protocol in humans, showing it to be effective and safe. The vaccine consists of an initial injection of viral DNA, which ‘primes’ the immune system to the pathogen, followed by a follow-up injection of an inactivated purified viral protein, which further boosts the host’s production of protective antibodies. The study shows the viability of this vaccine regimen and suggests further investigation into its appropriateness for treating avian influenza in humans.Adam D. DeZureEmily E. CoatesZonghui HuGalina V. YamshchikovKathryn L. ZephirMary E. EnamaSarah H. PlummerIngelise J. GordonFlorence KaltovichSarah AndrewsAdrian McDermottMichelle C. CrankRichard A KoupRichard M. SchwartzRobert T. BailerXiangjie SunJohn R. MascolaTerrence M. TumpeyBarney S. GrahamJulie E. LedgerwoodNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 2, Iss 1, Pp 1-6 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Adam D. DeZure Emily E. Coates Zonghui Hu Galina V. Yamshchikov Kathryn L. Zephir Mary E. Enama Sarah H. Plummer Ingelise J. Gordon Florence Kaltovich Sarah Andrews Adrian McDermott Michelle C. Crank Richard A Koup Richard M. Schwartz Robert T. Bailer Xiangjie Sun John R. Mascola Terrence M. Tumpey Barney S. Graham Julie E. Ledgerwood An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
description	Avian influenza: A vaccine for a deadly emergent strain A vaccine candidate to treat a deadly subtype of avian influenza was shown to induce protective antibodies in initial clinical trials. As of March 2017, avian influenza strain A/H7N9 has killed 497 people since 2013, with 1349 confirmed cases. Julie Ledgerwood and her team from the United States’ National Institutes of Health in collaboration with colleagues at the Centers for Disease Control and Prevention tested their two-stage vaccine protocol in humans, showing it to be effective and safe. The vaccine consists of an initial injection of viral DNA, which ‘primes’ the immune system to the pathogen, followed by a follow-up injection of an inactivated purified viral protein, which further boosts the host’s production of protective antibodies. The study shows the viability of this vaccine regimen and suggests further investigation into its appropriateness for treating avian influenza in humans.
format	article
author	Adam D. DeZure Emily E. Coates Zonghui Hu Galina V. Yamshchikov Kathryn L. Zephir Mary E. Enama Sarah H. Plummer Ingelise J. Gordon Florence Kaltovich Sarah Andrews Adrian McDermott Michelle C. Crank Richard A Koup Richard M. Schwartz Robert T. Bailer Xiangjie Sun John R. Mascola Terrence M. Tumpey Barney S. Graham Julie E. Ledgerwood
author_facet	Adam D. DeZure Emily E. Coates Zonghui Hu Galina V. Yamshchikov Kathryn L. Zephir Mary E. Enama Sarah H. Plummer Ingelise J. Gordon Florence Kaltovich Sarah Andrews Adrian McDermott Michelle C. Crank Richard A Koup Richard M. Schwartz Robert T. Bailer Xiangjie Sun John R. Mascola Terrence M. Tumpey Barney S. Graham Julie E. Ledgerwood
author_sort	Adam D. DeZure
title	An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
title_short	An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
title_full	An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
title_fullStr	An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
title_full_unstemmed	An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
title_sort	avian influenza h7 dna priming vaccine is safe and immunogenic in a randomized phase i clinical trial
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/e2d2da024d7c4739ac5a7e10fb271246
work_keys_str_mv	AT adamddezure anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT emilyecoates anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT zonghuihu anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT galinavyamshchikov anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT kathrynlzephir anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT maryeenama anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT sarahhplummer anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT ingelisejgordon anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT florencekaltovich anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT sarahandrews anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT adrianmcdermott anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT michelleccrank anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT richardakoup anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT richardmschwartz anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT roberttbailer anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT xiangjiesun anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT johnrmascola anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT terrencemtumpey anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT barneysgraham anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT julieeledgerwood anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT adamddezure avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT emilyecoates avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT zonghuihu avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT galinavyamshchikov avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT kathrynlzephir avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT maryeenama avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT sarahhplummer avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT ingelisejgordon avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT florencekaltovich avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT sarahandrews avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT adrianmcdermott avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT michelleccrank avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT richardakoup avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT richardmschwartz avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT roberttbailer avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT xiangjiesun avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT johnrmascola avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT terrencemtumpey avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT barneysgraham avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT julieeledgerwood avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial
_version_	1718384204816842752

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

Ejemplares similares